Company: Poolbeg Pharma (POLB)
Date: 9 June 2022
Presenters: Jeremy Skillington (CEO) and Cathal Friel (Chairman)
Company Information: Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company, with a capital light clinical model which aims to develop multiple products faster and more cost effectively than the conventional biotech model. Led by a team with a track record of creation and delivery of shareholder value, it aspires to become a “one-stop shop” for Big Pharma seeking mid-stage products to license / acquire.
Poolbeg is targeting the fast-growing infectious disease market which is expected to exceed $250bn by 2025.
With access to knowledge, experience, and clinical data from over 20 years of human challenge trials, Poolbeg is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. It has an expanding pipeline of assets, with the first POLB 001 due to enter the clinic in June 2022 with results expected in H2 2022 and monetisation through partnering / out-licencing to pharma / biotech thereafter.
Jeremy Skillington – CEO
Jeremy began is biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech he was responsible for executing over 40 licensing, investment and collaboration transactions. Returning to Ireland in 2009, he then led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd.
He then joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September, 2020 for €380M (£325M) upfront and significant downstream milestone payments.
Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D. He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck.
Cathal Friel – Chairman
Cathal is the Executive Chairman and Co-Founder of Open Orphan plc which IPO’d on the London and Dublin stock exchanges in June 2019. In 2021, Open Orphan completed a spin-out of one of its non-core assets to form Poolbeg Pharma plc, an infectious disease company with a capital light model, where Cathal is Chairman.
He also co-founded Amryt Pharma plc in 2015 along with Joe Wiley, which is listed on the London stock exchange since 2016 and which listed on Nasdaq in July 2020. Prior to Amryt, Cathal founded Fastnet Oil & Gas plc in 2011 which he IPO’d on the London stock exchange. Cathal was a finalist in the International category as part of the EY Entrepreneur of the Year 2020.
If you are already a member of ShareSoc you must log in prior to registering, then just click “REGISTER” below. If you are not already a member of ShareSoc, please complete the form below to sign up as an Associate member and then click “REGISTER”.
Click here for help on logging in.
Once you have registered you will receive an email notification, as well as reminders 1 day and 1 hour before the event starts.